Literature DB >> 24811546

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Caroline M Perry1, Greg L Plosker.   

Abstract

Sevelamer carbonate (Renvela(®)), a buffered form of sevelamer hydrochloride (Renagel(®)), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥ 1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24811546     DOI: 10.1007/s40265-014-0215-7

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  114 in total

1.  RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.

Authors:  E A Slatopolsky; S K Burke; M A Dillon
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

2.  Progression of cardiac valve calcification and decline of renal function in CKD patients.

Authors:  Luca Di Lullo; Fulvio Floccari; Alberto Santoboni; Vincenzo Barbera; Rodolfo Fernando Rivera; Antonio Granata; Luigi Morrone; Domenico Russo
Journal:  J Nephrol       Date:  2013-06-28       Impact factor: 3.902

3.  Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.

Authors:  A E M Stinghen; S M Gonçalves; S Bucharles; F S Branco; B Gruber; A B Hauser; R Pecoits-Filho
Journal:  Blood Purif       Date:  2010-03-31       Impact factor: 2.614

4.  Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.

Authors:  Kazuhiro Yamada; Shouichi Fujimoto; Takeshi Tokura; Keiichi Fukudome; Hideyuki Ochiai; Hiroyuki Komatsu; Yuji Sato; Seiichiro Hara; Tanenao Eto
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

5.  Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients.

Authors:  Iwao Ohno; Yuichiro Yamaguchi; Hajime Saikawa; Daijiro Uetake; Miho Hikita; Hideaki Okabe; Kimiyoshi Ichida; Tatsuo Hosoya
Journal:  Intern Med       Date:  2009-03-16       Impact factor: 1.271

6.  The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.

Authors:  David Pierce; Stuart Hossack; Lynne Poole; Antoine Robinson; Heather Van Heusen; Patrick Martin; Michael Smyth
Journal:  Nephrol Dial Transplant       Date:  2010-10-04       Impact factor: 5.992

7.  Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease.

Authors:  Domenico Russo; Antonio Bellasi; Andrea Pota; Luigi Russo; Biagio Di Iorio
Journal:  J Nephrol       Date:  2014-03-06       Impact factor: 3.902

Review 8.  Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

Authors:  Marcello Tonelli; Natasha Wiebe; Bruce Culleton; Helen Lee; Scott Klarenbach; Fiona Shrive; Braden Manns
Journal:  Nephrol Dial Transplant       Date:  2007-10       Impact factor: 5.992

9.  The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

Authors:  Anne-Kathrin Pieper; Franziska Buhle; Steffen Bauer; Ingrid Mai; Klemens Budde; Dieter Haffner; Hans-Hellmut Neumayer; Uwe Querfeld
Journal:  Nephrol Dial Transplant       Date:  2004-08-10       Impact factor: 5.992

Review 10.  Phosphate control in dialysis.

Authors:  Adamasco Cupisti; Maurizio Gallieni; Maria Antonietta Rizzo; Stefania Caria; Mario Meola; Piergiorgio Bolasco
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-10-04
View more
  5 in total

Review 1.  A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

Authors:  Wendy L St. Peter; Lori D Wazny; Eric Weinhandl; Katie E Cardone; Joanna Q Hudson
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

2.  Calcitriol-mediated hypercalcemia secondary to granulomatous disease caused by soft-tissue filler injection: a case report.

Authors:  Jairo Arturo Noreña; César Daniel Niño; Sabrina Gallego; Carlos Alfonso Builes-Barrera; Diva Cristina Castro; Alejandro Román-González; Camilo Jimenez
Journal:  Clin Cases Miner Bone Metab       Date:  2017-12-27

3.  Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.

Authors:  Khalidur Rahman; Chirayu Desai; Smita S Iyer; Natalie E Thorn; Pradeep Kumar; Yunshan Liu; Tekla Smith; Andrew S Neish; Hongliang Li; Shiyun Tan; Pengbo Wu; Xiaoxiong Liu; Yuanjie Yu; Alton B Farris; Asma Nusrat; Charles A Parkos; Frank A Anania
Journal:  Gastroenterology       Date:  2016-06-21       Impact factor: 22.682

4.  Sevelamer crystals in the mucosa of the gastrointestinal tract in a teenager with end-stage renal disease.

Authors:  Joseph Kim; Kristin Olson; Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2015-11-13       Impact factor: 3.714

Review 5.  Phosphate binders as a cause of hypothyroidism in dialysis patients: practical indications from a review of the literature.

Authors:  Emanuela Cataldo; Valeria Columbano; Louise Nielsen; Lurlynis Gendrot; Bianca Covella; Giorgina Barbara Piccoli
Journal:  BMC Nephrol       Date:  2018-07-02       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.